Loading...

Loncar Cancer Immunotherapy ETF

CNCRNASDAQ
Financial Services
Asset Management
$9.02
$0.14(1.58%)
U.S. Market opens in 4h 37m

Loncar Cancer Immunotherapy ETF (CNCR) Stock Competitors & Peer Comparison

See (CNCR) competitors and their performances in Stock Market.

Peer Comparison Table: Asset Management Industry

Detailed financial metrics including price, market cap, P/E ratio, and more.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
CNCR$9.02+1.58%7MN/AN/AN/A
VTSAX$156.23+2.50%2.1T24.43$6.21+1.20%
VITSX$156.26+2.50%2.1T24.43$6.21+1.32%
VSMPX$293.11+2.50%2.1T24.43$11.65+1.13%
PMFLX$10.01+0.30%1.9TN/AN/AN/A
VOO$597.55+2.86%1.6T25.81$23.15+1.19%
VFFSX$319.44+2.52%1.5T25.09$12.37N/A
VFIAX$602.47+2.52%1.5T25.09$23.33+1.12%
VFINX$602.60+2.52%1.5T25.09$23.33+1.19%
BCTK$23.33+5.03%1.1T41.24$0.57N/A
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

CNCR vs VTSAX Comparison April 2026

CNCR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNCR stands at 7M. In comparison, VTSAX has a market cap of 2.1T. Regarding current trading prices, CNCR is priced at $9.02, while VTSAX trades at $156.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNCR currently has a P/E ratio of N/A, whereas VTSAX's P/E ratio is 24.43. In terms of profitability, CNCR's ROE is +0.00%, compared to VTSAX's ROE of +0.08%. Regarding short-term risk, CNCR is more volatile compared to VTSAX. This indicates potentially higher risk in terms of short-term price fluctuations for CNCR.Check VTSAX's competition here

Stock price comparison of stocks in the Financial Services Sector

Loading...

Frequently Asked Questions